1 Min Read
May 23 (Reuters) - Cytori Therapeutics Inc-
* Cytori Therapeutics Inc - now completed all 48 week follow up monitoring visits in its U.S. FDA approved phase III star trial Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.